TPST · Tempest Therapeutics, Inc.

Summary

Tempest Therapeutics, Inc. entered a Securities Purchase Agreement on March 20, 2026, for a private placement issuing up to 462,964 shares or 462,963 pre-funded warrants, each with Series A and Series B warrants to purchase 925,927 shares, expecting approximately $2.0 million in gross proceeds for working capital and general corporate purposes.

Key takeaways

• Entered Securities Purchase Agreement on March 20, 2026 with two institutional investors and Factor Bioscience Inc.
• Private placement of 462,964 shares of Common Stock or 462,963 pre-funded warrants, each accompanied by Series A and Series B warrants for 925,927 shares.
• Combined purchase price of $2.16 per Share and warrants or $2.159 per Pre-Funded Warrant and warrants; gross proceeds ~$2.0 million.
• Closing expected on or about March 23, 2026, subject to customary conditions.
• Common Warrants exercisable post-Stockholder Approval at $2.16 per share; Series A term 5 years, Series B 24 months.
• H.C. Wainwright & Co., LLC as placement agent with 6% fee on institutional proceeds and 3% on strategic investor.